Ketamine clinic marketing
Ketamine clinic marketing that educates first.
People considering ketamine therapy have usually tried other treatments and have a lot of questions. We help clinics answer them honestly, explain screening and safety, and build the kind of trust that leads to a consultation.
4.9 on Clutch 5.0 on GoogleBoutique team in Orange County, CABehavioral health specialists
Written by Ara Bedelian, Founder & CEO7+ years in behavioral health marketing · Updated
For ketamine and Spravato providers
The short answer
What ketamine clinic marketing should do.
Ketamine clinic marketing helps clinics reach adults who are exploring ketamine or esketamine (Spravato) for depression and related conditions. It should explain who may be a candidate, how screening and sessions work, safety monitoring, cost and insurance, and the difference between FDA-approved Spravato and off-label ketamine, without promising results. Search, local listings and a clear consultation path do the rest.
Accuracy protects you
Ketamine marketing draws regulatory and public attention. Clear, accurate claims protect your clinic and your patients.
Education builds candidates
Most visitors are researching. Pages that answer their questions honestly turn that research into consultations.
Referrals matter
Psychiatrists and therapists often refer ketamine patients. Pages and resources for referrers can be as valuable as patient search.
The ketamine marketing guide
Marketing ketamine and Spravato carefully and honestly.
Key takeaways
- Spravato (esketamine) is FDA-approved for treatment-resistant depression; IV ketamine for depression is off-label.
- Spravato can only be given in certified settings with at least two hours of monitoring after each dose.
- FDA has warned about compounded and at-home ketamine products, so clinics should be careful about how they describe treatment.
- Education wins: most visitors are researching after other treatments have not worked.
- Referring clinicians and clear screening information are as important as search.
Know the regulatory picture
Ketamine marketing sits in a sensitive space. Spravato, a nasal spray form of esketamine, was approved by the FDA in 2019 for treatment-resistant depression, later for depressive symptoms in adults with major depressive disorder with acute suicidal thoughts or behavior, and in 2025 as a standalone treatment for treatment-resistant depression. Ketamine itself is FDA-approved as an anesthetic, so IV ketamine for depression is used off-label.
| Spravato (esketamine) | IV ketamine | |
|---|---|---|
| FDA status for depression | Approved (2019, expanded 2020 and 2025) | Off-label use |
| Where it is given | Certified healthcare settings only (REMS) | Clinic setting, per clinic protocols |
| Monitoring | At least 2 hours after each dose | Per clinic protocols |
| Insurance | Often covered with prior authorization | Usually self-pay |
| Take-home use | Never dispensed for home use | Not applicable |
Who is visiting your website
Most people researching ketamine or Spravato have already tried other treatments. They are hopeful but cautious, and often skeptical of anything that sounds like hype. Many are also family members or referring clinicians. Content that is honest, specific and well sourced converts better than bold promises.
The pages a ketamine clinic needs
- Spravato page, accurate about approval and REMS
- IV ketamine page, clear about off-label use
- Candidacy and screening, including who is not a fit
- Safety and monitoring, step by step
- Cost and insurance, with honest ranges
- What a session is like, before, during and after
- Referring provider page and process
- Integration and therapy, if you offer it
Claims we will and will not make
We describe treatment plainly, cite research carefully and make approval status clear. We avoid words like “cure,” success rates without a source, and anything that downplays side effects or suggests treatment is right for everyone. Your medical director reviews every clinical claim before publishing.
Advertising limits
Ad platforms restrict promotion of controlled substances and some related treatments, and policies change. Our work focuses on organic search, local visibility, referrals and owned channels, which do not depend on ad approvals.
Referral relationships
Psychiatrists and therapists often refer patients for ketamine or Spravato, and some patients continue therapy alongside treatment. A referral page with criteria, intake steps and how you communicate with the referring clinician builds trust with the people most likely to send patients your way.
Local search and reviews
Local visibility matters because treatment requires repeated in-person visits. A complete Google Business Profile, accurate listings and a respectful review process help. We avoid confirming in public responses that a reviewer received treatment.
Integration and therapy content
Many clinics pair ketamine with psychotherapy or integration sessions. Explaining how those pieces fit together, who provides them and what patients can expect helps set realistic expectations and positions your clinic as thoughtful rather than transactional.
Candidacy and screening content
People want to know whether they might be a candidate before they call. A candidacy page should explain the kinds of situations where ketamine or Spravato may be considered, such as depression that has not improved after other treatments, and be equally clear that a medical evaluation decides eligibility. It is also appropriate to explain that some health conditions can affect whether treatment is safe, without listing a self-diagnosis checklist.
- Who may be considered, in plain language
- Why screening matters and what it includes
- Health factors your team reviews, described generally
- What happens if you are not a fit, and other options
- How referrals work from a current provider
- Questions to bring to the consultation
Being honest about cost
Cost is the biggest practical question for IV ketamine, which is usually self-pay. Publishing a price range or a starting price, explaining what is included and describing payment options builds far more trust than “call for pricing.” For Spravato, explaining how insurance and prior authorization typically work helps patients understand their options.
| Topic | What to explain |
|---|---|
| IV ketamine | Price per session or series, what is included, payment options |
| Spravato | Insurance coverage, prior authorization and visit structure |
| Consultation | Whether it is free or billed, and what it covers |
| Follow-up care | Maintenance sessions or integration therapy costs |
Measuring results
We track consultation requests by source, and where possible how many become treatment starts. That shows whether your content attracts the right people, not just more people.
Sources
- FDA, FDA approves new nasal spray medication for treatment-resistant depression (2019): www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified
- Johnson & Johnson, Spravato approved as monotherapy for treatment-resistant depression (January 2025): www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression
- Spravato REMS: www.spravatorems.com/
- FDA, Compounding risk alerts (ketamine, 2022 and 2023): www.fda.gov/drugs/human-drug-compounding/compounding-risk-alerts
What’s included
Marketing for ketamine clinics.
Careful content, local search and a clear path to consultation.
Treatment pages
Separate pages for IV ketamine, Spravato and ketamine-assisted therapy, each accurate about approval status.
Candidacy and safety content
Who may be a fit, screening steps, monitoring during sessions and what recovery looks like after.
Cost and insurance
Clear pricing or ranges, what insurance may cover (often Spravato), and payment options.
Referral provider resources
A page and simple process for clinicians referring patients.
Local SEO
Google Business Profile, listings and reviews for each clinic location.
Website design
A calm, credible site with a consultation request. See mental health website design.
How it works
How we work with ketamine clinics.
Review
Your treatments, protocols, pricing and current claims.
Plan
Pages for each treatment and the questions people ask.
Build
Content, local search and the consultation path.
Refine
Monthly reporting on consult requests and rankings.
Claims
What we will and will not say.
This is where many ketamine clinics get into trouble. We keep your marketing on solid ground.
What we won’t write
- “Cures depression” or similar promises
- Success rates without a clear source
- Implying IV ketamine is FDA-approved for depression
- Messaging that downplays risks
What we write instead
- Plain descriptions of what treatment involves
- Research cited carefully, with sources
- Clear notes on approval status and off-label use
- Honest information on side effects and screening
CreateFlo has exceeded our expectations across all areas of the project.
Our work
Mental health providers we’ve helped grow.
Client reviews
Rated 5.0 on Google and 4.9 on Clutch.
GoogleWhat clients say on Google
How do ketamine clinics get more patients?
Through clear, accurate treatment information, strong local search, referral relationships with other clinicians and a simple consultation process.
Can we advertise ketamine on Google?
Google and other platforms restrict some ads related to ketamine and controlled substances. Our work focuses on organic search, local visibility, referrals and your website, which do not depend on ad approvals.
Do you market Spravato?
Yes. Spravato is FDA-approved for treatment-resistant depression and has its own requirements, so it gets its own page.
Will you review our existing claims?
Yes. We flag claims that could be misleading and suggest accurate alternatives for your medical director to approve.
Do you work with ketamine-assisted psychotherapy practices?
Yes. We help explain how the therapy and medication pieces work together.
Can we say ketamine treats depression?
You can describe IV ketamine as an off-label treatment being used for depression and cite research carefully. Avoid implying FDA approval for that use.
What about at-home ketamine?
FDA has warned about compounded ketamine products used at home. We do not create messaging that promotes unsupervised use.
Do you market Spravato to referring clinicians?
Yes. Clear referral information and REMS-related logistics help clinicians refer appropriate patients with confidence.
About the author
Ara Bedelian
Ara has spent more than seven years working with addiction treatment centers and mental health providers on website design, branding and search engine optimization. His work spans every stage of how someone finds treatment, from the first Google search to the moment they decide to call.
Keep exploring
Related services.
More for mental health providers
Free website audit
Ready to grow with a partner who cares?
Tell us a little about your organization. We’ll review your website and search presence and share clear, practical recommendations — free.
- ✓A personalized website & SEO review
- ✓Clear next steps, no jargon
- ✓No obligation, no pressure
Prefer to talk? Call (949) 394-7041